Document is current
Any future updates will be listed below
-
Authors
Li, Jiao https://orcid.org/0000-0002-8027-5877
Huang, Kaimeng https://orcid.org/0000-0002-0552-209X
Thakur, Meha
McBride, Fiona
Sadagopan, Ananthan
Gallant, Daniel S.
Khanna, Prateek
Laimon, Yasmin Nabil
Li, Bingchen
Mohanna, Razan
Ge, Maolin
Weiss, Cary N.
Achom, Mingkee https://orcid.org/0000-0002-7908-3368
Xu, Qingru
Matar, Sayed
Lee, Gwo-Shu Mary
Huang, Kun https://orcid.org/0000-0002-9100-9638
Gui, Miao
Wu, Chin-Lee
Cornejo, Kristine M.
Choueiri, Toni K. https://orcid.org/0000-0002-9201-3217
Ryback, Birgitta A.
Signoretti, Sabina
Bar-Peled, Liron https://orcid.org/0000-0003-2687-9546
Viswanathan, Srinivas R. https://orcid.org/0000-0003-1856-3023
-
Funding
Funding for this research was provided by:
Doris Duke Charitable Foundation (2020101)
U.S. Department of Defense (W81XWH-22-1-016, W81XWH-22-1-0399)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA279044, R01CA286652, 1R21CA226082-01, R37CA260062, R01CA279044)
Damon Runyon Cancer Research Foundation (71-22)
Rally Foundation (23IN37)
Kidney Cancer Association
American Association for Cancer Research
Dana-Farber/Harvard Cancer Center (2P50CA101942-16, 5P30CA006516-56)
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 9 January 2025
First Online: 6 February 2025
Competing interests
: S.R.V. has consulted for Jnana Therapeutics within the past 3 years and receives research support from Bayer. L.B.-P. is a co-founder, holds equity in and is a consultant for Scorpion Therapeutics. T.K.C. reports institutional and/or personal paid and/or unpaid support for research, advisory board, consultancy, and/or honoraria past 5 years from Alkermes, Arcus Bio, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Bicycle Therapeutics, Calithera, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GSK, Gilead, HiberCell, IQVA, Infinity, Institut Servier, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Neomorph, Nuscan/PrecedeBio, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME and non-CME events (Mashup Media Peerview, OncLive, MJH, CCO and others), outside the submitted work; institutional patents filed on molecular alterations and immunotherapy response/toxicity, and ctDNA; equity from Tempest, Pionyr, Osel, PrecedeBio, CureResponse, InnDura Therapeutics, and Primium, Abalytics; is a committee member for NCCN, the GU Steering Committee, ASCO, ESMO, ACCRU, and KidneyCan; medical writing and editorial assistance support that might have been founded by communications companies in part, no speaker’s bureau; mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/foreign components; the institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. S.S. reports receiving commercial research grants from Bristol Myers Squibb, AstraZeneca, Exelixis and Novartis; is a consultant/advisory board member for Merck & Co., Rahway, NJ, AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics AG, AACR and NCI; and receives royalties from Biogenex. The other authors declare no competing interests.
